|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results showed that the AZ628 and BP-1-102 combination showed strongly synergistic effects on KRAS(G12D) H838, KRAS(G12S) H292 and KRAS(G12V) H441 cells and significantly enhanced the inhibition of cell proliferation <i>in vitro</i> and tumor growth <i>in vivo</i> by promoting apoptosis compared with one inhibitor alone.
|
31484165 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Liquid biopsy profiling of circulating tumor DNA revealed the acquisition of KRAS proto-oncogene, GTPase (<i>KRAS</i>) p.G12C mutation, indicating the occurrence of another resistance mechanism to erlotinib.
|
31186738 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
While ameloblastomas show BRAF p.V600E mutations, adenomatoid odontogenic tumours harbour either KRAS p.G12R or p.G12 V. The lack of understanding of the core molecular changes involved in tumour initiation and progression represents a critical barrier to developing new strategies for cancer detection and prevention.
|
31543246 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genotyping of resistant cells identified gene amplification of EGFR, KRAS, and mutant BRAF, as well as acquired mutations in KRAS, EGFR, and MAP2K1 These mechanisms were clinically relevant, as we identified emergence of a KRAS G12C mutation and increase of mutant BRAF V600E allele frequency in the circulating tumor DNA of a patient at relapse from combined treatment with BRAF and MEK inhibitors.
|
27312529 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
|
27358379 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
DNA was extracted from tumor and plasma samples and tested for the common codon 12 mutations G12D, G12V, and G12C by chip-based digital PCR.
|
27591291 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In vivo, activation of apoptosis (TUNEL) and reduction of proliferation (Ki67) after treatment with regorafenib were more pronounced in KRAS WT tumors as compared with G12C variants.
|
26161928 |
2015 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with KRAS-G12C mutant tumors had significantly shorter DFS compared with other KRAS mutants and KRAS wild-type tumors (p < 0.001).
|
25170638 |
2014 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Strength of fascin expression and tumor percentage stained with fascin were scored semi quantitatively. c.34 > C (p.G12R), c.35 g > C (p.G12C), c.34G > A (p.G12S), c.35G > A (p.G12D), c.35G > T (p.G12V), c.35G > C (p.G12A), and c.38G > A (p.G13.D) mutations in K-RAS gene were studied by using RT-PCR.
|
23588415 |
2014 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, during anti-EGFR treatment, it came to the selection of cells with KRAS G12C mutation which were present from the beginning in the tumor but at a low level (detected by PCR methods) only and led consequently to the metastasis.
|
23606169 |
2013 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients whose tumors had either mutant KRas-Gly12Cys or mutant KRas-Gly12Val had worse progression-free survival compared with patients whose tumors had other mutant KRas proteins or wild-type KRas (P = .046, median survival = 1.84 months) compared with all other mutant KRas (median survival = 3.35 months) or wild-type KRas (median survival = 1.95 months).
|
22247021 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Most of the patients (82.8%) had a KRAS wild type tumor; a p.Gly12Cys was found in three patients and a p.Gly12Val mutation in one.
|
22668015 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
One tumor harbored a missense mutation in the c-Kit (p.F504L) and in the KRAS gene (p.G12S).
|
21131919 |
2011 |